GEXVal GEXVal Senior Director to Present at LINK-J/AMED Drug Discovery Venture Event

株式會社GEXVal
September 2, 2025

GEXVal Senior Director to Present at LINK-J/AMED Co-hosted Event "Current State of Drug Discovery Venture Ecosystem"

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that Dr. Taketoshi Kobayashi, Senior Director of Clinical Development Unit, will present at the "Current State of Drug Discovery Venture Ecosystem" event, co-hosted by the Life Science Innovation Network Japan (LINK-J) and the Japan Agency for Medical Research and Development (AMED), following an invitation from AMED.

[Event Overview]
This event aims to share insights on the current state and potential of drug discovery venture support, providing opportunities for industry-academia collaboration and new business creation. The event is expected to serve as a platform for further promoting AMED's Drug Discovery Venture Ecosystem Enhancement Program and fostering mutual understanding and dialogue between venture capital firms and startups.

**Presentation Details**

[GEXVal's AMED Grant Recognition]
GEXVal has been selected for AMED's FY2024 "Strengthening Program for Pharmaceutical Startup Ecosystem." For more details, please refer to our previous news release:
GEXVal Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem'
https://gexval.com/en/rd-en/gexval-selected-for-ameds-strengthening-program-for-pharmaceutical-startup-ecosystem/

[About LINK-J]
The Life Science Innovation Network Japan (LINK-J) is a general incorporated association established in 2016 by Mitsui Fudosan Co., Ltd., a major real estate developer of the Mitsui Group, together with academia and industry stakeholders. Based in Nihonbashi, Tokyo's historic pharmaceutical district with over 400 years of drug business heritage dating back to the Shogun period (Edo period), LINK-J promotes open innovation and ecosystem building across the life sciences spectrum, fostering collaboration among industry, government, academia, and venture companies both domestically and internationally.
For more information: https://www.link-j.org/en/about/overseas/

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com